Clinical data for intravenous iron - debunking the hype around hypersensitivity.

ABSTRACT:

Background

Reluctance to use intravenous (IV) iron for the treatment of iron deficiency continues due to a perceived high risk of severe hypersensitivity reactions (HSRs). Additionally, it has been hypothesized that 'dextran-derived' IV iron products (e.g., ferumoxytol [FER] and ferric derisomaltose/iron isomaltoside 1000 [FDI]) have a higher risk of severe HSRs than 'non-dextran-derived' products (e.g., ferric carboxymaltose [FCM] and iron sucrose [IS]). In the present analysis, HSR data from head-to-head randomized controlled trials (RCTs) with IV iron products were evaluated to determine if differences in safety signals are present among these IV iron formulations.

Study design and methods

Reported serious or moderate-to-severe HSR incidence data from five RCTs (FIRM; FER

SUBMITTER: Achebe M 

PROVIDER: S-EPMC7384172 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature